# Oriola Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/oriola). ## Overview Oriola is a Nordic pharmaceutical company that operates in the distribution and wholesale of pharmaceuticals and health products across Finland and Sweden. The company focuses on providing logistics services, dose dispensing, and advisory services to healthcare providers and pharmacies. Oriola has strengthened its market position through strategic acquisitions and investments in advanced distribution centers. The company is committed to sustainability, having set ambitious climate targets validated by the Science Based Targets initiative. ## Products & services • Pharmaceutical logistics and distribution • Dose dispensing services • Wholesale of OTC products and special licensed medicines • Advisory services for pharmaceutical companies • Commercial data solutions • Parallel import of pharmaceuticals - **Distribution** (60%) — Includes pharmaceutical logistics and dose dispensing services. - **Wholesale** (30%) — Covers OTC products, special licensed medicines, and parallel import. - **Advisory Services** (10%) — Offers consulting and data solutions for pharmaceutical companies. - Pharmaceutical logistics and distribution - Dose dispensing services - Wholesale of OTC products and special licensed medicines - Advisory services for pharmaceutical companies - Commercial data solutions - Parallel import of pharmaceuticals ## Customers Oriola serves a diverse range of customers including pharmacies, hospitals, veterinarians, and other healthcare providers in Finland and Sweden. The company provides dose dispensing services to both private and public healthcare sectors, enhancing patient safety with pre-dispensed medications. Oriola's wholesale segment caters to retail and online markets, ensuring the availability of health and wellness products. The advisory services segment supports pharmaceutical companies with market entry and regulatory compliance in the Nordic region. - **Pharmacies** (primary) — Purchase logistics and wholesale services for efficient supply. - **Hospitals** (primary) — Rely on Oriola for dose dispensing and pharmaceutical logistics. - **Veterinarians** (secondary) — Source special licensed medicines and OTC products. - **Healthcare Providers** (emerging) — Use advisory services for regulatory compliance. - Pharmacies purchase logistics and wholesale services for efficient supply. - Hospitals rely on Oriola for dose dispensing and pharmaceutical logistics. - Veterinarians source special licensed medicines and OTC products. - Healthcare providers use advisory services for regulatory compliance. - Retailers benefit from Oriola's distribution of health and wellness products. ## Geography Oriola operates primarily in Finland and Sweden, with a strong presence in the Nordic pharmaceutical distribution market. The company has significant market shares in both countries, with 42% in Sweden and 46% in Finland. Oriola's logistics and distribution centers are strategically located to support efficient operations across these regions. The company's recent investments in a new distribution center in Järvenpää, Finland, aim to enhance capacity and sustainability. - Operates in Finland and Sweden with significant market shares. - Distribution centers strategically located for efficient operations. - New distribution center in Järvenpää to increase capacity by 30%. - Strong presence in Nordic pharmaceutical distribution market. - Investments in sustainability and energy efficiency in Finland. ## Strategy Oriola's strategic priorities include reinforcing customer focus, expanding value-adding services, and improving operational efficiency. The company is investing in advanced distribution infrastructure and IT systems to support growth and sustainability goals. Oriola aims to strengthen its position in the Nordic advisory market through acquisitions and partnerships. The focus on sustainability is reflected in ambitious climate targets and investments in energy-efficient facilities. - **Customer Focus** (short-term) — To enhance service delivery and customer satisfaction. - **Infrastructure Investment** (medium-term) — To support growth and operational efficiency. - **Sustainability** (long-term) — To align with climate targets and reduce emissions. - Reinforcing customer focus to enhance service delivery. - Expanding value-adding services to drive growth. - Investing in advanced distribution and IT infrastructure. - Strengthening position in Nordic advisory market through acquisitions. - Commitment to sustainability with ambitious climate targets. ## Risks Oriola faces several risks including regulatory changes in the pharmaceutical industry, supply chain disruptions, and geopolitical uncertainties. The company's operations are subject to strict regulations, and any non-compliance could impact its business. Supply chain constraints and cost inflation pose challenges to profitability. Additionally, cybersecurity threats and market volatility could affect operations and financial performance. - **Regulatory Changes** [high] — Strict regulations in pharmaceutical distribution. - **Supply Chain Disruptions** [critical] — Constraints affecting product availability. - **Geopolitical Uncertainties** [high] — Influencing market conditions and operations. - **Cybersecurity Threats** [high] — Potential impact on critical operations. - Regulatory changes impacting pharmaceutical distribution. - Supply chain disruptions affecting product availability. - Geopolitical uncertainties influencing market conditions. - Cost inflation and salary inflation impacting profitability. - Cybersecurity threats posing risks to operations. ## Accounting Oriola's financial reporting is prepared in accordance with IFRS standards, with particular attention to revenue recognition and segment reporting. The company must carefully manage estimates and provisions related to regulatory compliance and legal proceedings. Lease accounting under IFRS 16 impacts reported liabilities and expenses. The timing of revenue recognition, especially in advisory services, can affect quarterly results. - **Revenue Recognition** — medium - **Lease Accounting** — medium - **Estimates and Provisions** — high - Revenue recognition timing affects quarterly results. - Lease accounting under IFRS 16 impacts liabilities. - Estimates and provisions for regulatory compliance. - Segment reporting provides insights into business performance. --- *Last updated: 2026-08-11T04:04:55.118216+00:00*